Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jan;37(1):376-379.
doi: 10.1007/s13577-023-01014-1. Epub 2023 Nov 24.

Estrogen receptor- and progesterone receptor-positive breast tumors have higher mRNA levels of NR3C1 and ZBTB16, with implications in prognosis for luminal A subtype

Caglar Berkel  1
Affiliations
Comment

Estrogen receptor- and progesterone receptor-positive breast tumors have higher mRNA levels of NR3C1 and ZBTB16, with implications in prognosis for luminal A subtype

Caglar Berkel. Hum Cell. 2024 Jan.
No abstract available

PubMed Disclaimer

Comment on

  • Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.
    Prekovic S, Chalkiadakis T, Roest M, Roden D, Lutz C, Schuurman K, Opdam M, Hoekman L, Abbott N, Tesselaar T, Wajahat M, Dwyer AR, Mayayo-Peralta I, Gomez G, Altelaar M, Beijersbergen R, Győrffy B, Young L, Linn S, Jonkers J, Tilley W, Hickey T, Vareslija D, Swarbrick A, Zwart W. Prekovic S, et al. EMBO Mol Med. 2023 Dec 7;15(12):e17737. doi: 10.15252/emmm.202317737. Epub 2023 Oct 30. EMBO Mol Med. 2023. PMID: 37902007 Free PMC article.

References

    1. Prekovic S, Chalkiadakis T, Roest M, Roden D, Lutz C, Schuurman K, Opdam M, Hoekman L, Abbott N, Tesselaar T, Wajahat M, Dwyer AR, Mayayo-Peralta I, Gomez G, Altelaar M, Beijersbergen R, Győrffy B, Young L, Linn S, Jonkers J, Tilley W, Hickey T, Vareslija D, Swarbrick A, Zwart W. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity. EMBO Mol Med. 2023. https://doi.org/10.15252/emmm.202317737 . - DOI - PubMed - PMC
    1. He J, Wu M, Xiong L, Gong Y, Yu R, Peng W, Li L, Li L, Tian S, Wang Y. BTB/POZ zinc finger protein ZBTB16 inhibits breast cancer proliferation and metastasis through upregulating ZBTB28 and antagonizing BCL6/ZBTB27. Clin Epigenetics. 2020;12:1–15. - DOI
    1. Tonsing-Carter E, Hernandez KM, Kim CR, Harkless RV, Oh A, Bowie KR, West-Szymanski DC, Betancourt-Ponce MA, Green BD, Lastra RR. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association. Breast Cancer Res. 2019;21:1–15. - DOI
    1. Yang F, Ma Q, Liu Z, Li W, Tan Y, Jin C, Ma W, Hu Y, Shen J, Ohgi KA. Glucocorticoid receptor: MegaTrans switching mediates the repression of an ERα-regulated transcriptional program. Mol Cell. 2017;66: e326. - DOI
    1. Pan D, Kocherginsky M, Conzen S. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 2011;71:6360–70. - DOI - PubMed - PMC

LinkOut - more resources